US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

42.68

-1.3200-3.00%

Post-market: 42.680.00000.00%19:30 EDT

Volume:189.31K

Turnover:8.07M

Market Cap:2.05B

PE:-13.98

High:43.98

Open:43.87

Low:41.76

Close:44.00

52wk High:52.93

52wk Low:23.75

Shares:47.98M

Float Shares:30.39M

Volume Ratio:0.56

T/O Rate:0.62%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0525

EPS(LYR):-2.8633

ROE:-39.96%

ROA:-25.78%

PB:4.84

PE(LYR):-14.91

Loading ...

Overview Company News Filings

Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million

Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics announces annual shareholder meeting

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Third Rock Ventures V disposes of Rapport Therapeutics shares worth $17.2 million

Rapport CDO Krishnaswamy sells 20,225 shares for $808,844

Rapport Therapeutics presents results from Phase 2a trial of RAP-219

Rapport Therapeutics Inc: Rap-219 Was Generally Well Tolerated Throughout Treatment and Follow-up Periods

THOMSON REUTERS

Rapport Therapeutics says RAP-219 Phase 2a follow-up sustains seizure reductions in focal seizures

Rapport Therapeutics Chief Development Officer Krishnaswamy sells USD 696,440 shares

Rapport Therapeutics Chief Development Officer Krishnaswamy sells $12,564 common shares

Rapport Therapeutics initiated with a Strong Buy at Raymond James

Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?

Simply Wall St.

Harmony Biosciences names Peter Anastasiou COO in executive reshuffle

Rapport Therapeutics to present new Phase 2a follow-up data for RAP-219 in seizures

Assessing Rapport Therapeutics (RAPP) Valuation After Zacks Rank Upgrade And Strong One Year Return

Simply Wall St.

Rapport Therapeutics; Chief Development Officer Yeleswaram Krishnaswamy sells 10,115 common shares for $303,000

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/RAPP/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":42.68,"timestamp":1789502400000,"preClose":44,"halted":0,"volume":189312,"hourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.68,"latestTime":"19:30 EDT","volume":6223,"amount":265597.64,"timestamp":1789515006342,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.030000000000000006,"floatShares":30393800,"shares":47978286,"eps":-3.052456,"marketStatus":"Not Yet Opened","change":-1.32,"latestTime":"09-15 16:00:00 EDT","open":43.87,"high":43.98,"low":41.76,"amount":8067192.01152,"amplitude":0.050455,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.052456,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":44,"preHourTrading":{"tag":"盘前","latestPrice":42.32,"preClose":44,"latestTime":"08:01 EDT","volume":205,"amount":9020.2296,"timestamp":1789473717136,"change":-1.68,"changeRate":-0.038182,"amplitude":0.106364},"postHourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.68,"latestTime":"19:30 EDT","volume":6223,"amount":265597.64,"timestamp":1789515006342,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.558408,"impliedVol":1.475,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":30393800,"roa":"-25.78%","roe":"-39.96%","lyrEps":-2.863342,"volumeRatio":0.558408,"shares":47978286,"dividePrice":0,"high":43.98,"amplitude":0.050455,"preClose":44,"low":41.76,"week52Low":23.75,"pbRate":"4.84","psRate":"102.39","week52High":52.93,"institutionHeld":0,"latestPrice":42.68,"eps":-3.052456,"divideRate":0,"volume":189312,"delay":0,"ttmEps":-3.052456,"open":43.87,"prevYearClose":30.34,"prevWeekClose":43.62,"prevMonthClose":48.67,"prevQuarterClose":41.67,"fiveDayClose":46.09,"twentyDayClose":48.42,"sixtyDayClose":37.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"RAPP","fiscalQuarterEnding":"2026/06","expectedEps":-0.93,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2026-05-07","symbol":"RAPP","fiscalQuarterEnding":"2026/03","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.42},{"market":"US","date":"2026-03-10","symbol":"RAPP","fiscalQuarterEnding":"2025/12","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-06","symbol":"RAPP","fiscalQuarterEnding":"2025/09","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4615,"buy":0.5385,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1785211200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2026-09-14","current":-13.982184,"percent":0.230634,"low":-19.654107,"twenty":-15.752225,"median":-12.913036,"eighty":-6.452088,"high":-3.640031,"avg":-11.790591,"sd":4.390366,"marketCap":2092812835},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-17","current":-12.986138,"twenty":-13.856058,"median":-9.228454,"eighty":-5.262092,"marketCap":1146831851},{"date":"2025-10-24","current":-13.675391,"twenty":-13.856058,"median":-9.397898,"eighty":-5.294604,"marketCap":1207701093},{"date":"2025-10-31","current":-14.035682,"twenty":-13.934383,"median":-9.502263,"eighty":-5.303959,"marketCap":1239519106},{"date":"2025-11-07","current":-11.969573,"twenty":-13.970933,"median":-9.588184,"eighty":-5.319746,"marketCap":1169427252},{"date":"2025-11-14","current":-12.034803,"twenty":-13.934383,"median":-9.698265,"eighty":-5.33408,"marketCap":1175800274},{"date":"2025-11-21","current":-13.098276,"twenty":-13.915585,"median":-9.917175,"eighty":-5.342242,"marketCap":1279701555},{"date":"2025-11-28","current":-14.493474,"twenty":-13.931568,"median":-10.309179,"eighty":-5.356195,"marketCap":1416012409},{"date":"2025-12-05","current":-14.000764,"twenty":-13.954437,"median":-10.426271,"eighty":-5.376155,"marketCap":1367874660},{"date":"2025-12-12","current":-14.039791,"twenty":-13.99491,"median":-10.604143,"eighty":-5.393122,"marketCap":1371687551},{"date":"2025-12-19","current":-14.459326,"twenty":-14.050476,"median":-10.719003,"eighty":-5.431972,"marketCap":1412676130},{"date":"2025-12-26","current":-15.088628,"twenty":-14.119227,"median":-10.841851,"eighty":-5.476848,"marketCap":1474158998},{"date":"2026-01-02","current":-14.800808,"twenty":-14.281097,"median":-10.940782,"eighty":-5.513507,"marketCap":1446038926},{"date":"2026-01-09","current":-13.81051,"twenty":-14.281097,"median":-10.976093,"eighty":-5.513507,"marketCap":1349286816},{"date":"2026-01-16","current":-13.103154,"twenty":-14.237527,"median":-11.048158,"eighty":-5.513507,"marketCap":1280178166},{"date":"2026-01-23","current":-13.620256,"twenty":-14.172521,"median":-11.156822,"eighty":-5.535473,"marketCap":1330698972},{"date":"2026-01-30","current":-13.049493,"twenty":-14.13499,"median":-11.312246,"eighty":-5.592253,"marketCap":1274935441},{"date":"2026-02-06","current":-12.464095,"twenty":-14.128014,"median":-11.370643,"eighty":-5.617345,"marketCap":1217742075},{"date":"2026-02-13","current":-13.644647,"twenty":-14.087483,"median":-11.410917,"eighty":-5.641114,"marketCap":1333082029},{"date":"2026-02-20","current":-14.630067,"twenty":-14.14031,"median":-11.45735,"eighty":-5.660027,"marketCap":1429357528},{"date":"2026-02-27","current":-14.391029,"twenty":-14.240388,"median":-11.53826,"eighty":-5.735139,"marketCap":1406003571},{"date":"2026-03-06","current":-14.464204,"twenty":-14.259247,"median":-11.689515,"eighty":-5.790087,"marketCap":1413152741},{"date":"2026-03-13","current":-12.292686,"twenty":-14.284564,"median":-11.721364,"eighty":-5.811144,"marketCap":1370425569},{"date":"2026-03-20","current":-11.773881,"twenty":-14.259247,"median":-11.747556,"eighty":-5.859217,"marketCap":1312587588},{"date":"2026-03-27","current":-12.434179,"twenty":-14.240388,"median":-11.754185,"eighty":-5.89508,"marketCap":1386199565},{"date":"2026-04-02","current":-13.578981,"twenty":-14.21307,"median":-11.781033,"eighty":-5.908305,"marketCap":1513825524},{"date":"2026-04-10","current":-14.672331,"twenty":-14.286297,"median":-11.799793,"eighty":-5.924837,"marketCap":1635715486},{"date":"2026-04-17","current":-16.95336,"twenty":-14.342463,"median":-11.834618,"eighty":-5.953085,"marketCap":1890011406},{"date":"2026-04-24","current":-15.589888,"twenty":-14.384981,"median":-11.842483,"eighty":-5.987204,"marketCap":1738007454},{"date":"2026-05-01","current":-14.207247,"twenty":-14.395165,"median":-11.879676,"eighty":-6.003597,"marketCap":1583866549},{"date":"2026-05-08","current":-17.794666,"twenty":-14.442977,"median":-11.889648,"eighty":-6.018516,"marketCap":1908958386},{"date":"2026-05-15","current":-16.919116,"twenty":-14.478378,"median":-11.936812,"eighty":-6.027747,"marketCap":1815031955},{"date":"2026-05-22","current":-16.361832,"twenty":-14.513564,"median":-11.969573,"eighty":-6.033101,"marketCap":1755248294},{"date":"2026-05-29","current":-17.605688,"twenty":-14.602401,"median":-12.072587,"eighty":-6.039697,"marketCap":1888685426},{"date":"2026-06-05","current":-16.714035,"twenty":-14.636423,"median":-12.104204,"eighty":-6.052541,"marketCap":1793031568},{"date":"2026-06-12","current":-15.697551,"twenty":-14.689254,"median":-12.211886,"eighty":-6.082711,"marketCap":1683986170},{"date":"2026-06-18","current":-16.437623,"twenty":-14.725074,"median":-12.249449,"eighty":-6.104202,"marketCap":1763378872},{"date":"2026-06-26","current":-17.347109,"twenty":-14.756903,"median":-12.285702,"eighty":-6.170327,"marketCap":1860945807},{"date":"2026-07-02","current":-17.561106,"twenty":-14.865035,"median":-12.307654,"eighty":-6.173633,"marketCap":1883902733},{"date":"2026-07-10","current":-18.747004,"twenty":-14.94702,"median":-12.322165,"eighty":-6.184379,"marketCap":2011122364},{"date":"2026-07-17","current":-17.891017,"twenty":-15.011798,"median":-12.351888,"eighty":-6.210003,"marketCap":1919294660},{"date":"2026-07-24","current":-18.4483,"twenty":-15.085362,"median":-12.382727,"eighty":-6.318283,"marketCap":1979078322},{"date":"2026-07-31","current":-19.072457,"twenty":-15.112377,"median":-12.415031,"eighty":-6.358759,"marketCap":2046036022},{"date":"2026-08-07","current":-16.213135,"twenty":-15.201543,"median":-12.451899,"eighty":-6.368734,"marketCap":2223793556},{"date":"2026-08-14","current":-16.566431,"twenty":-15.503178,"median":-12.623979,"eighty":-6.396893,"marketCap":2272251624},{"date":"2026-08-21","current":-16.737832,"twenty":-15.582924,"median":-12.704769,"eighty":-6.419712,"marketCap":2295760985},{"date":"2026-08-28","current":-17.780229,"twenty":-15.689526,"median":-12.798103,"eighty":-6.426595,"marketCap":2438736277},{"date":"2026-09-04","current":-16.667872,"twenty":-15.740131,"median":-12.897046,"eighty":-6.440085,"marketCap":2286165327},{"date":"2026-09-11","current":-15.202219,"twenty":-15.758139,"median":-12.908089,"eighty":-6.450467,"marketCap":2085136309},{"date":"2026-09-14","current":-15.258186,"twenty":-15.752225,"median":-12.913036,"eighty":-6.452088,"marketCap":2092812835}],"updateTime":1789532380947},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633459211","title":"Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459211?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:03","pubTimestamp":1778151822,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics posted a Q1 net loss of USD 19.9 million, narrowing from USD 24.1 million a year earlier, while loss per share improved to USD 0.42 from USD 0.68.Collaboration revenue was USD 20 million versus no revenue a year earlier, while R&D expense rose to USD 32.7 million from USD 19.6 million.G&A expense climbed to USD 11.5 million from USD 7.5 million; cash, cash equivalents and short-term investments ended at USD 476.8 million, down from USD 490.5 million at year-end.Phase 2a follow-up data for RAP-219 in focal onset seizures showed a 90% median reduction in clinical seizures over baseline in weeks 9-12; RAP-219 half-life estimate was raised to 22 days from 14 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL1t8R84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633814551","title":"Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633814551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633814551?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Phase 2a follow-up period data for RAP-219 in focal onset seizures  demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12. RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance. Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and <ALPHA>6<BETA>4 nAChR in chronic pain and migraine, continue to advance. Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications. \"We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,\" said Abraham N. Cees","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4181","BK4007","PK","BK4178","AAN","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835569","title":"Rapport Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835569?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:22","pubTimestamp":1776943333,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics scheduled 2026 annual shareholder meeting for June 10, 2026 in virtual format.Shareholders will vote to elect Class II directors James Healy, Robert Perez, Raymond Sanchez to terms running to 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL8rpgJj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629884497","title":"Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2629884497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629884497?lang=en_us&edition=fundamental","pubTime":"2026-04-23 17:42","pubTimestamp":1776937320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 05:42 ET (09:42 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706901","title":"Third Rock Ventures V disposes of Rapport Therapeutics shares worth $17.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706901","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706901?lang=en_us&edition=fundamental","pubTime":"2026-04-22 07:36","pubTimestamp":1776814611,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V sold 426,005 shares of Rapport Therapeutics common stock on April 17.Sale priced at weighted average USD 40.32 per share.Third Rock Ventures V held 6,709,228 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL2SNvVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Third Rock Ventures V disposes of Rapport Therapeutics shares worth $17.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629206388","title":"Rapport CDO Krishnaswamy sells 20,225 shares for $808,844","url":"https://stock-news.laohu8.com/highlight/detail?id=2629206388","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629206388?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:55","pubTimestamp":1776804939,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 20,225 common shares on April 17, 2026.Sale price was USD 39.99 per share on a weighted-average basis.Trade was executed under a Rule 10b5-1 plan adopted Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLcdrNTm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport CDO Krishnaswamy sells 20,225 shares for $808,844","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629068134","title":"Rapport Therapeutics presents results from Phase 2a trial of RAP-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2629068134","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629068134?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:39","pubTimestamp":1776803943,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures, FOS, in a late-br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-presents-results-from-phase-2a-trial-of-rap-219-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-presents-results-from-phase-2a-trial-of-rap-219-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629068520","title":"Rapport Therapeutics Inc: Rap-219 Was Generally Well Tolerated Throughout Treatment and Follow-up Periods","url":"https://stock-news.laohu8.com/highlight/detail?id=2629068520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629068520?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:36","pubTimestamp":1776803789,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN4140LX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629556068","title":"Rapport Therapeutics says RAP-219 Phase 2a follow-up sustains seizure reductions in focal seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2629556068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629556068?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:32","pubTimestamp":1776803570,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics presented follow-up results from Phase 2a trial of RAP-219 in focal onset seizures at 2026 American Academy of Neurology Annual Meeting on April 21, 2026.Data showed seizure control remained durable beyond end of dosing, with clinical outcomes holding up through 16 weeks of drug exposure.Pharmacokinetic analyses supported a longer drug persistence than previously estimated, reinforcing rationale for less frequent dosing.Safety profile remained broadly consistent through follow-up, with no new treatment-related serious safety signals reported.Company plans to start two pivotal Phase 3 trials in focal onset seizures in Q2 2026, with initial open-label long-term safety data expected in 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL8q46F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014013.SGD","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","BK4112","SG9999014021.USD","BK4007","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4588","RAPP","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627421941","title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells USD 696,440 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421941","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421941?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:14","pubTimestamp":1776197669,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares in transactions dated April 10 to April 14.Sales prices ranged from USD 34.97 to USD 35.08 per share.Krishnaswamy’s direct holding fell to 266,651 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL7rR8C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells USD 696,440 shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626213075","title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells $12,564 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626213075","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626213075?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:31","pubTimestamp":1775766713,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares on April 8, 2026 at USD 34.9 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4PTT8y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells $12,564 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130194","title":"Rapport Therapeutics initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130194?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:15","pubTimestamp":1775765715,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Rapport Therapeutics (RAPP) with a Strong Buy rating and $66 price target Published first on TheFly – the ultim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BGHQF748.EUR","LU2265009873.SGD","BK4585","RAPP","LU1804176565.USD","BK4127","BK4588","LU1363072403.SGD","BK4007","LU0971096721.USD","IE00B3QW5Z07.USD","RJF","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624965535","title":"Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624965535","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624965535?lang=en_us&edition=fundamental","pubTime":"2026-04-03 15:26","pubTimestamp":1775201170,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. announced it will present Phase 2a trial results for RAP-219 in focal onset seizures, including 8-week follow-up data, at the American Academy of Neurology Annual Meeting in Chicago on April 18–22, 2026.\nThe focus on TARPγ8, a protein expressed in specific brain regions linked to seizure origins but with minimal hindbrain presence, highlights a precision approach that may differentiate RAP-219 from broader-acting neuroscience therapies.\nWe’ll examine how the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/is-rapport-therapeutics-rapp-turning-its-tarp8-precision-sei","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/is-rapport-therapeutics-rapp-turning-its-tarp8-precision-sei","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","BK4587","AIYY","AI","BK4007","BK4551","BK4588","CHAT","AIPO","RAPP","AGIX","BK4543","BK4585","BK4023","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624064645","title":"Harmony Biosciences names Peter Anastasiou COO in executive reshuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=2624064645","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624064645?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:07","pubTimestamp":1775131628,"startTime":"0","endTime":"0","summary":"Harmony Biosciences appointed Peter Anastasiou as chief operating officer.Anastasiou previously served on Harmony board, most recently was CEO of Capsida Biotherapeutics.Harmony named Troy Ignelzi to board to fill vacancy created by Anastasiou resignation; Ignelzi is CFO of Rapport Therapeutics.Ignelzi previously served as CFO of Karuna Therapeutics, where he led capital raises including IPO.Board nominated Geno J. Germano for election at 2026 annual meeting; Germano most recently was CEO of Elucida Oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire  on April 02, 2026, and is solely responsible for the information c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL5mNs8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","BK4534","LU0061475181.USD","LU0096364046.USD","LU1074936037.SGD","LU2133065610.SGD","LU0237698245.USD","IE00BJJMRZ35.SGD","BK4007","LU1670710661.SGD","BK4585","LU1261432733.SGD","IE00BFTCPJ56.SGD","HRMY","LU0882574055.USD","LU1670711040.USD","RAPP","LU0114720955.EUR","LU0868494617.USD","IE00BSNM7G36.USD","LU1291159041.SGD","LU1670710588.SGD","LU1571399168.USD","LU1989771016.USD","LU0225284248.USD","LU0985481810.HKD","LU1093756325.SGD","BK4581","LU0321505439.SGD","LU1430594728.SGD","IE0002141913.USD","LU2125154935.USD","BK4559","LU1093756168.USD","LU0456855351.SGD","LU1868836757.USD","LU2360032135.SGD","LU1585245621.USD","LU1883839398.USD","LU1718418525.SGD","BMY","LU0306806265.USD","LU1868837300.USD","LU0321505868.SGD","IE00B2B36J28.USD","LU1868836914.USD","LU1868836591.USD","BK4532","LU0225771236.USD","LU2125154778.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624459748","title":"Rapport Therapeutics to present new Phase 2a follow-up data for RAP-219 in seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2624459748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624459748?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:01","pubTimestamp":1775041280,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics scheduled new Phase 2a follow-up results for RAP-219 in focal onset seizures for presentation at American Academy of Neurology Annual Meeting on April 21, 2026.Data will cover an 8-week post-treatment follow-up period from trial, focusing on efficacy and tolerability signals.Update is positioned to inform clinical and development strategy for RAP-219 as a potential first-in-class program in focal onset seizures.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL257DXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4007","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD","SG9999014013.SGD","BK4588","IE00BN0W2V16.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","BK4112","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623535437","title":"Assessing Rapport Therapeutics (RAPP) Valuation After Zacks Rank Upgrade And Strong One Year Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2623535437","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623535437?lang=en_us&edition=fundamental","pubTime":"2026-03-29 23:05","pubTimestamp":1774796756,"startTime":"0","endTime":"0","summary":"Why Rapport Therapeutics (RAPP) is back on traders' radar\nRapport Therapeutics (RAPP) has drawn fresh attention after a recent upgrade to a Zacks Rank #2 (Buy), tied to higher earnings estimates that suggest improving sentiment around the company’s profit outlook.\nSee our latest analysis for Rapport Therapeutics.\nDespite a recent 1-day share price decline of 4% to US$27.84 and a mixed near-term pattern, Rapport Therapeutics still shows a very strong 1-year total shareholder return of 177.01%,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/assessing-rapport-therapeutics-rapp-valuation-after-zacks-ra","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/assessing-rapport-therapeutics-rapp-valuation-after-zacks-ra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622992328","title":"Rapport Therapeutics; Chief Development Officer Yeleswaram Krishnaswamy sells 10,115 common shares for $303,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622992328","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622992328?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:42","pubTimestamp":1774557741,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy reported a sale of 10,115 common shares on 03/25/2026.The shares were sold at a weighted average price of USD 29.99 per share.Following the transaction, Krishnaswamy beneficially owned 286,876 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2gdfVc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics; Chief Development Officer Yeleswaram Krishnaswamy sells 10,115 common shares for $303,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":77,"code":"91000000","status":"200"}]}}